Methods to reduce postoperative surgical site infections after head and neck oncology surgery
Reviewer : Ramandeep Kaur
Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer
Depression and survival in head and neck cancer patients
How common is hypothyroidism after external radiotherapy to neck in head and neck cancer patients?
Reviewer : Nirmala Srikantia
Swallowing sparing IMRT vs Parotid sparing IMRT in head and neck cancer: Phase III randomized trial
Sensorineural hearing loss in patients with head and neck cancer treated with chemoradiotherapy
Reviewer : Deepanjali Adulkar
Panel Discussion On Complications In Head And Neck Cancers
External beam radiation with or without concurrent chemotherapy in non-anaplastic thyroid cancer with unresectable or gross residual disease
Reviewer : Ashish Agrawal
Adenoid cystic carcinoma of head and neck: A single institutional analysis of 66 patients treated with multi-modality approach
Moderator : Ajeet Kumar Gandhi
Treatment-emergent hypertension and efficacy in the phase 3 study of (e7080) Levatinib in differentiated cancer of the thyroid (SELECT)
Efficacy and safety of Vinorelbine plus Cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck
Reviewer : Bharat Chauhan
Prolonged duration of response in Levatinib responders with thyroid cancers
Reviewer : Avinash Pandey
Panel Discussion On Rare HN cancers and thyroid cancers
1042O Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study
Nivolumab vs Investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of checkmate 141 with analyses by tumor PD-L1 expression
Nivolumab vs Investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck analysis of checkmate 141 by age
Estimated costs of Treatment-Related Adverse Events (TRAES) for Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the checkmate 141 trial
Reviewer : Priyanka Srivastav
Health-Related Quality of Life (HRQOL) of Pembrolizumab (PEMBRO) vs Standard of Care (SOC) for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in Keynote-040
Reviewer : Sushant Mittal
Electrochemotherapy for mucosal head and neck Tumours: Results from a phase II clinical trial
Interpreting indeterminate post-treatment PET/CT results in patients with head and neck squamous cell carcinoma
Panel Discussion On Immunotherapy and Electrochemotherapy
Moderator : Sandeep Goyle